Clinical trials: Schizophrenia Disorders
Schizophrenia, Schizoaffective Disorder
Cerebellar Modulation of Cognition in Psychosis
The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I, Psychosis
- Trial name
- NCT06107764
- Testing
- intermittant theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Mclean Hospital
Deep Brain Stimulation
Efficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders
This is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of combo-stim deep brain stimulation for treatment-refractory mental disorders (obsessive-compulsive disorder…
- Trial name
- NCT06112067
- Testing
- deep brain stimulation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Mental Health Center
SCHIZOPHRENIA 1 (Disorder), Borderline Personality Disorder
Disorders of the Sense of Self and Physical Activity
Schizophrenia (SZ) patients with metabolic syndrome, patients with vestibular syndrome, and patients with borderline personality disorder, would benefit from physical activity (PA).
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Borderline Personality Disorder, Vestibular Syndromes
- Trial name
- sensdesoi (NCT06817980)
- Testing
- Physical activity
- Where
- France
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia Spectrum Disorder
Personalized Metacognitive Training for Psychosis: A Randomized Controlled Trial
This study aims to compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis.
- Trial name
- PERMEPSY (NCT07146802)
- Testing
- Metacognitive Training (MCT) for psychosis
- Where
- France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Strasbourg, France
Bipolar Disorder, Schizophrenia
COMpassion for Psychiatric Disorders And Self-Stigma
People with mental disorders face frequent stigmatizing attitudes and behaviors from others . In response to this, they tend to isolate themselves, with the risk of impeding care and the process of recovery and integration into…
- Conditions
- Bipolar Disorder, Schizophrenia, Depression, Borderline Personality Disorder
- Trial name
- COMPASS (NCT05698589)
- Testing
- Compassion Focused Therapy, Ending Self Stigma
- Where
- 7 sites in France
- Volunteers
- 336 people
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia, Schizoaffective Disorder
Enhancing Veteran-Clinical Collaboration in VA PRRCs
Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Bipolar Disorder
- Trial name
- EVCC VPRRC (NCT06898879)
- Testing
- Collaborative Decision Skills Training, Leveling Up
- Where
- 3 sites in United States
- Volunteers
- 119 people
- Sponsor
- VA Office of Research and Development
Schizophrenia Disorder
Assessment of Physical Activity, Balance, Muscle Strength, and Cognitive Function in Patients Diagnosed With Schizophrenia
Schizophrenia is a serious mental health condition that affects individuals' thinking, perception, emotional responses, and behavior.
- Trial name
- NCT07141966
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
SCHIZOPHRENIA 1 (Disorder)
Basal Stimulation Therapy in Adults With Schizophrenia Requiring Institutional Care
The aim of the study is to obtain knowledge of the impact of basal stimulation therapy on the health status of adults suffering from schizophrenia and requiring permanent institutional care.
- Trial name
- NCT07769749
- Testing
- physiotherapy, 2 x a week for 6 weeks, basal therapy, 2 x a week for 6 weeks, Standard therapy group
- Where
- 2 sites in Poland
- Volunteers
- 12 people
- Sponsor
- The Jerzy Kukuczka Academy of Physical Education in Katowice
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia Spectrum Disorders (SSD)
Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment
Research on schizophrenia spectrum disorders (SSD) patients with social impairment is essential for improving treatment, enhancing the lives of affected individuals, reducing stigma, and advancing our understanding of this…
- Trial name
- OXY-APS (NCT06881810)
- Testing
- Oxytocin nasal spray
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia, Schizo Affective Disorder
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
The purpose of this study is to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
- Trial name
- NCT07006935
- Testing
- Clubhouse Model of Psychosocial Rehabilitation for Serious Mental Illness, Usual Community-Based Mental Health Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Case Western Reserve University
Bipolar I Disorder, Schizophrenia
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
- Trial name
- NCT04987229
- Testing
- OLZ/SAM
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 236 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Bipolar I Disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
- Trial name
- NCT05303064
- Testing
- OLZ/SAM, Olanzapine
- Where
- 47 sites in United States, Argentina and 3 more
- Volunteers
- 220 people
- Sponsor
- Alkermes, Inc.
Severe Mental Disorder
Aerobic, Resistance and Inspiratory Muscle Training in Adults With Severe Mental Disorder
People with severe mental disorder, such as schizophrenia, bipolar disorder or major depression, tend to have poorer physical health and a shorter life expectancy than the general population.
- Trial name
- NCT07758049
- Testing
- Supervised multicomponent exercise programme
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- Universidad Pablo de Olavide
Paranoid Schizophrenia, Schizophrenia and Related Disorders
Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for "Paranoia".
The study is a randomised, assessor-blinded parallel-groups superiority clinical trial fulfilling the CONSORT criteria for non-pharmacological treatment.
- Conditions
- Paranoid Schizophrenia, Schizophrenia and Related Disorders, Schizophrenia Prodromal, Schizotypal Disorder
- Trial name
- FYF (NCT04902066)
- Testing
- Cognitive Behavioural Virtual Reality Therapy., Traditional Cognitive Behavioural Therapy
- Where
- Denmark
- Volunteers
- 259 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia Schizoaffective
Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes
Two of the major features of schizophrenia spectrum illness, negative and cognitive symptoms, have been associated with poor functional outcome and burden of illness.
- Trial name
- NCT05414058
- Testing
- Apo-Methylphenidate ER
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia and Schizoaffective Disorder
A Trial of Group Cognitive Behavioral Therapy for Psychosis (the Feeling Safe Programme)
Schizophrenia is a serious psychiatric disorder characterized by delusions, hallucinations, negative symptoms and disorganized behaviour.
- Trial name
- NCT07408934
- Testing
- Cognitive Behavioral Therapy for Psychosis
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Royal Ottawa Mental Health Centre
SCHIZOPHRENIA 1 (Disorder)
A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia
The primary purpose of this open-label phase 3 study is to evaluate the safety of HS-10380 on the incidence, severity, relationship to investigational product of adverse events (AE), serious adverse events (SAE), and adverse…
- Trial name
- NCT07759869
- Testing
- HS-10380
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Agitation, Schizophrenia
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia.
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- SERENITY I (NCT04268303)
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc